Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhysiomics Regulatory News (PYC)

Share Price Information for Physiomics (PYC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.30
Bid: 1.20
Ask: 1.40
Change: -0.20 (-13.33%)
Spread: 0.20 (16.667%)
Open: 1.25
High: 1.30
Low: 1.05
Prev. Close: 1.50
PYC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading update

10 May 2021 07:00

RNS Number : 9967X
Physiomics PLC
10 May 2021
 

10 May 2021

 

Physiomics plc

("Physiomics") or ("the Company")

 

Trading update

 

 

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, today announces that its total income for the financial year ending 30 June 2021 is likely to be in the range of £700k-£800k and its loss after tax in the range of £170-200k. This is below market expectations and due to both COVID related project delays and to an increased focus on longer-term value-generating activities. The Company's cash position remains strong, and it is estimated that on 30 June 2021 its net asset position will be c.£1.1m, the majority of which is cash.

 

Although the biotech and pharma industries have not been impacted by COVID to the same extent as many other industries, the precautions taken by hospitals to reduce patient exposure to COVID-related risks has meant a number of trials either being suspended or experiencing slower recruitment. This has impacted the Company both in terms of delays to its own personalised PARTNER dosing study and associated NIHR funding and due to delays in client trials that have led to data being received by the Company later than expected. Despite this, the Directors continue to believe that the Company's shift in focus from mainly pre-clinical work to a mix that includes more higher-value clinical projects will lead to enhanced value as COVID-related pressures on healthcare systems moderate over the course of the rest of this calendar year.

 

The Directors also believe that the Company's selective engagement in activities that do not immediately generate revenue have the potential to deliver significant longer-term value. In particular, the initial work with TabulaRasa Healthcare® ("TRHC") to integrate Physiomics' personalised docetaxel model into TRHC's market-leading precision dosing solution, DoseMeRx is due to conclude within the next few months.

 

The Company is pleased to announce that, on 1 April 2021, it convened an advisory board meeting to discuss opportunities to grow both its core consulting and non-consulting businesses. The meeting was attended by the Directors of Physiomics, long-term consultant, Dr Hitesh Mistry, and external advisor and industry veteran, Dr Tim Corn. It is intended that advisory boards will be held on a regular basis, but at least annually and that further members with expertise in areas of interest will be added as required.

 

As announced in its Interim Results on 1 March 2021, the Company is actively considering how it could use its extensive capabilities in modelling, simulation, data analysis and AI techniques, to develop further innovative assets in collaboration with other partners, to complement its existing consulting and personalised medicine activities. Following extensive discussion, the advisory board identified a number of areas felt to have particular potential for the Company to explore further and the Directors have taken actions to investigate.

 

Directors have also ratified the hiring of a senior business development executive to increase the Company's capacity to secure new clients for its core consulting business. This search has already commenced and is expected to be completed by Q4 this year.

 

Dr Jim Millen, CEO, commented: "The pharmaceuticals and biotech industry has weathered the COVID storm better than many other sectors and industries, however it is not immune, and it is well known that trial delays have been a knock-on effect. We believe the impact on Physiomics will be temporary and we already see that clinical trials and patient recruitment are showing signs of returning to normality. We have continued to discuss with current clients a number of new projects and have also been in dialogue with a number of potential new clients."

 

This announcement is released by Physiomics plc and contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 (MAR), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 80 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.

 

 

About Dr Tim Corn

 

Dr Corn is an experienced lifesciences industry executive who has played pivotal roles in a number of companies. He currently serves as Non-executive Chairman of the Board of Reneuron plc, as Trustee of Nerve Tumours UK, and as Chief Medical Officer of both Izana Bioscience and Akasa Bioscience. He was formerly Chief Medical Officer at EUSA Pharma Inc (sold to Jazz Pharmaceticals in 2016), at Zeneus Pharma (sold to Cephalon in 2006), as well as Non-executive Director at Circassia Pharmaceuticals plc, HRA Pharma and Neurocentrx Pharma Ltd.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUPURPAUPGGUB
Date   Source Headline
1st Jul 20137:00 amRNSAdditional SEDA Drawdown
24th Jun 20137:00 amRNSWins Poster Award
20th Jun 20134:28 pmRNSAward of Grant
11th Jun 20137:00 amRNSPopulation Approach Group Europe
6th Jun 20137:00 amRNSVirtual Tumour Clinical Contract
8th Apr 20138:03 amRNSPhysiomics to present new developments
25th Mar 20137:00 amRNSPhysiomics to provide cardiac toxicity modelling
18th Mar 20137:00 amRNSNew clinical PK/PD modelling service
13th Feb 201311:10 amRNSIssue of Options
11th Feb 20133:23 pmRNSDirector Declaration
8th Feb 20137:00 amRNSHalf Yearly Report
22nd Jan 20137:00 amRNSSEDA Arrangement
7th Jan 20137:00 amRNSRecruitment of Senior Scientist with Clinical PK/P
18th Dec 20129:46 amRNSFrench R&D Tax Credit Accreditation
17th Dec 201212:29 pmRNSResult of AGM
14th Nov 20127:00 amRNSFinal Results for the year ended 30 June 2012
8th Oct 20128:38 amRNSNew US Business Development Consultant
10th Aug 20127:53 amRNSNew Agreement to optimise oncology combination
7th Aug 20123:57 pmRNSStmnt re Share Price Movement
4th Jul 20123:25 pmRNSTrading Update
7th Jun 201211:42 amRNSPresentation at the 2012 PAGE 21st Annual Meeting
29th May 201212:37 pmRNSShare Price Movement
21st May 201212:03 pmRNSDirector/PDMR Shareholding
30th Apr 20127:00 amRNSTotal Voting Rights
26th Apr 20128:49 amRNSIssue of Equity
29th Mar 20127:00 amRNSParticipation in AACR Annual Meeting 2012
16th Mar 20127:00 amRNSPhysiomics to present at the Bio-Europe Conference
7th Mar 20127:00 amRNSHalf Yearly Report
1st Mar 20127:20 amRNSNew Agreement with Global Pharma Company
31st Jan 201211:57 amRNSPhysiomics to enter new therapeutic area
20th Dec 201112:05 pmRNSIssue of Options
18th Nov 201110:07 amRNSResult of AGM
9th Nov 20115:01 pmRNSIssue of Options
2nd Nov 20117:00 amRNSExecution of New Agreement
19th Oct 20117:00 amRNSScientific Board Update
11th Oct 20118:39 amRNSFinal Results
29th Sep 201110:17 amRNSJoint servs alliance executed with Jubilant Biosys
27th May 201110:33 amRNSIssue of Equity
13th May 20114:34 pmRNSIssue of Equity
4th May 20117:00 amRNSNew collaboration with Pharmacometrics Limited
28th Apr 20119:46 amRNSTotal Voting Rights
6th Apr 20117:00 amRNSIssue of Equity
5th Apr 20117:00 amRNSUpcoming Presentation
1st Apr 201110:32 amRNSResults Update
29th Mar 20111:10 pmRNSIssue of Equity
9th Mar 20117:00 amRNSHalf Yearly Report
8th Mar 20117:00 amRNSUpdate: Joint services alliance w. Jubilant Biosys
15th Feb 20114:56 pmRNSStmnt re Share Price Movement
9th Feb 20119:25 amRNSStmnt re Share Price Movement
8th Feb 201111:47 amRNSStmnt re Share Price Movement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.